CELZ vs ILMN vs MESO vs PACB

For growth investors, Mesoblast Limited (MESO) is the stronger pick with 191.

4% revenue growth year-over-year, versus -45. 5% for Creative Medical Technology Holdings, Inc. (CELZ). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (26. 8x forward), making it the more compelling value choice. Analysts rate Illumina, Inc. (ILMN) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mesoblast Limited (MESO) delivered a total return of +6.

0%, compared to -98. 7% for Creative Medical Technology Holdings, Inc. (CELZ). Over 10 years, the gap is even starker: ILMN returned +0. 7% versus CELZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 23β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 97% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Mesoblast Limited (MESO) carries a lower debt/equity ratio of 21% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesoblast Limited (MESO) is pulling ahead at 191.

4% versus -45. 5% for Creative Medical Technology Holdings, Inc. (CELZ). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, MESO leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -999. 2% for Creative Medical Technology Holdings, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -1003. 2% for CELZ. At the gross margin level — before operating expenses — MESO leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ILMN: 6.

3% to $147. 38.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Illumina, Inc.

(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23)). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +0. 7%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CELZ is a small-cap quality compounder stock; ILMN is a mid-cap quality compounder stock; MESO is a small-cap high-growth stock; PACB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.